Echo Therapeutics

Echo Therapeutics, established in 1989, focuses on developing a non-invasive, wireless, continuous glucose monitoring (CGM) system. The company's CGM system holds potential for application in the outpatient diabetes market, as well as in the fitness, weight loss, and wearable-health sector. Additionally, it presents a longer-term opportunity in hospital settings. Echo has also introduced a needle-free skin preparation device as a platform technology, enabling improved skin permeation for the extraction of analytes, including glucose, and enhanced delivery of topical pharmaceuticals. The company, headquartered in the United States, received a $1.79M Post-IPO Debt investment on February 8, 2016. Although the last investment details do not specify the investors, this funding underscores investor interest in Echo Therapeutics' innovative approach in the Biotechnology, Health Care, Health and Wellness, and Medical Devices industries.